ADC Therapeutics SA
NYSE:ADCT
Intrinsic Value
ADC Therapeutics SA is a clinical-stage biotechnology company. [ Read More ]
The intrinsic value of one ADCT stock under the Base Case scenario is 6.57 USD. Compared to the current market price of 4.96 USD, ADC Therapeutics SA is Undervalued by 24%.
Valuation Backtest
ADC Therapeutics SA
Run backtest to discover the historical profit from buying and selling ADCT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
ADC Therapeutics SA
Current Assets | 336.3m |
Cash & Short-Term Investments | 278.6m |
Receivables | 25.2m |
Other Current Assets | 32.5m |
Non-Current Assets | 18.5m |
Long-Term Investments | 1.6m |
PP&E | 16.1m |
Other Non-Current Assets | 711k |
Current Liabilities | 67.7m |
Accounts Payable | 15.6m |
Accrued Liabilities | 50.6m |
Other Current Liabilities | 1.5m |
Non-Current Liabilities | 435.4m |
Long-Term Debt | 426.5m |
Other Non-Current Liabilities | 8.9m |
Earnings Waterfall
ADC Therapeutics SA
Revenue
|
69.6m
USD
|
Cost of Revenue
|
-2.5m
USD
|
Gross Profit
|
67m
USD
|
Operating Expenses
|
-233m
USD
|
Operating Income
|
-166m
USD
|
Other Expenses
|
-74.1m
USD
|
Net Income
|
-240.1m
USD
|
Free Cash Flow Analysis
ADC Therapeutics SA
What is Free Cash Flow?
ADCT Profitability Score
Profitability Due Diligence
ADC Therapeutics SA's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
Score
ADC Therapeutics SA's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
ADCT Solvency Score
Solvency Due Diligence
ADC Therapeutics SA's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
ADC Therapeutics SA's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADCT Price Targets Summary
ADC Therapeutics SA
According to Wall Street analysts, the average 1-year price target for ADCT is 10.4 USD with a low forecast of 8.08 USD and a high forecast of 13.65 USD.
Ownership
ADCT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ADCT Price
ADC Therapeutics SA
Average Annual Return | -37.33% |
Standard Deviation of Annual Returns | 45.24% |
Max Drawdown | -99% |
Market Capitalization | 409.3m USD |
Shares Outstanding | 82 530 000 |
Percentage of Shares Shorted | 1.84% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.
Contact
IPO
Employees
Officers
The intrinsic value of one ADCT stock under the Base Case scenario is 6.57 USD.
Compared to the current market price of 4.96 USD, ADC Therapeutics SA is Undervalued by 24%.